AR017138A1 - Compuestos antagonistas del neuropeptido y, formulaciones farmaceuticas que los incluyen, usos farmaceuticos de tales compuestos y procedimientos parala preparacion de los mismos. - Google Patents

Compuestos antagonistas del neuropeptido y, formulaciones farmaceuticas que los incluyen, usos farmaceuticos de tales compuestos y procedimientos parala preparacion de los mismos.

Info

Publication number
AR017138A1
AR017138A1 ARP980104740A ARP980104740A AR017138A1 AR 017138 A1 AR017138 A1 AR 017138A1 AR P980104740 A ARP980104740 A AR P980104740A AR P980104740 A ARP980104740 A AR P980104740A AR 017138 A1 AR017138 A1 AR 017138A1
Authority
AR
Argentina
Prior art keywords
compounds
alkoxy
halo
pharmaceutical
alkyl
Prior art date
Application number
ARP980104740A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR017138A1 publication Critical patent/AR017138A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuestos antagonista del neuropéptido Y de la formula (I), en la cual Ar1 representa un fragmento estructural de la formula (II) o representa 1-o 2-naftilo, estando este ultimo grupo optativamente sustituido con uno o más sustituyentes seleccionados entre OH, halo o alcoxi C1-7; R1 representaC(O)NH2, alquilo C1-4 (optativamente sustituido o terminado con uno o más sustituyentes seleccionados entre hidroxi o amino)o, junto con R7 (en Ar1),formas de alquileno C2-3; R4 representa H, alquilo C1-7o alquilenfenilo C1-4 (estando el grupo fenilo de este ultimo grupo optativamente sustituido conuno o más sustituyentes seleccionados entre OH o alcoxi C1-4); R5 y R6 representan independientemente H, OH, alquilo C1-4, alcoxi C1-4 o halo; R7 representaH, OH, o, junto con R1, forma alquileno C2-3; R8 representa H, halo, OH, alcoxi C1-7, fenilo, fenoxi, benciloxi, -(CH2)nC(O)N(R10)R11, -(CH2)nN(H)C(O)N(R10)R11o -O(CH2)nC(O)OR10; R9 representa H, halo, OH o alcoxi C1-7; R2, R3, R10 y R11 representan independientemente H o alquilo C1-7; especialmente utilizablesen el tratamiento de enfermedades cardiovasculares, por ejemplo la vasoconstriccion. Se describen también formulaciones farmacéuticas que incluyen adichos compuestos, usos farmacéuticosde los mismos y procedimientos para su preparacion.
ARP980104740A 1997-09-23 1998-09-22 Compuestos antagonistas del neuropeptido y, formulaciones farmaceuticas que los incluyen, usos farmaceuticos de tales compuestos y procedimientos parala preparacion de los mismos. AR017138A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703414A SE9703414D0 (sv) 1997-09-23 1997-09-23 New compounds

Publications (1)

Publication Number Publication Date
AR017138A1 true AR017138A1 (es) 2001-08-22

Family

ID=20408331

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104740A AR017138A1 (es) 1997-09-23 1998-09-22 Compuestos antagonistas del neuropeptido y, formulaciones farmaceuticas que los incluyen, usos farmaceuticos de tales compuestos y procedimientos parala preparacion de los mismos.

Country Status (21)

Country Link
US (1) US6127414A (es)
EP (1) EP1017672B1 (es)
JP (1) JP2001517651A (es)
KR (1) KR20010024220A (es)
CN (1) CN1279666A (es)
AR (1) AR017138A1 (es)
AT (1) ATE228500T1 (es)
AU (1) AU9288998A (es)
BR (1) BR9812492A (es)
CA (1) CA2303528A1 (es)
DE (1) DE69809782T2 (es)
EE (1) EE200000171A (es)
IL (1) IL134993A0 (es)
IS (1) IS5410A (es)
NO (1) NO20001483L (es)
PL (1) PL339617A1 (es)
SE (1) SE9703414D0 (es)
SK (1) SK3602000A3 (es)
TR (1) TR200000785T2 (es)
WO (1) WO1999015498A1 (es)
ZA (1) ZA988353B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802075D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
US6312898B1 (en) * 1999-04-15 2001-11-06 Hormos Medical Oy, Ltd. Diagnosis of a person's risk of developing atherosclerosis or diabetic retinopathy based on leucine 7 to proline 7 polymorphism in the prepro-neuropeptide Y gene
SE9902596D0 (sv) * 1999-07-06 1999-07-06 Astra Ab Pharmaceutically active compounds
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
SE0101328D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Therapeutic treatment
JP4010951B2 (ja) * 2001-05-15 2007-11-21 大正製薬株式会社 アルギニン誘導体
JP4806628B2 (ja) 2003-05-05 2011-11-02 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤
EP2338490A3 (en) 2003-11-03 2012-06-06 Probiodrug AG Combinations useful for the treatment of neuronal disorders
FR2864830B1 (fr) * 2004-01-06 2006-03-10 Centre Nat Rech Scient Procede de synthese sur support solide de composes peptidiques, notamment de composes peptidiques comportant un residu arginine
BRPI0507485A (pt) 2004-02-05 2007-07-10 Probiodrug Ag inibidores novos de glutaminil ciclase
FR2884516B1 (fr) * 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
KR100689499B1 (ko) * 2005-10-26 2007-03-02 삼성전자주식회사 휴대단말기에서 키 설정 정보 디스플레이 방법
WO2007064272A1 (en) * 2005-11-29 2007-06-07 Astrazeneca Ab Benzhydryl amide derivatives as cannabinoid receptor antagonists or inverse agonists
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
US20240226343A1 (en) * 2022-11-23 2024-07-11 Radionetics Oncology, Inc. Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5873821A (en) * 1992-05-18 1999-02-23 Non-Invasive Technology, Inc. Lateralization spectrophotometer
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19544687A1 (de) * 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19544686A1 (de) * 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AU2242197A (en) * 1996-01-09 1997-08-01 Eli Lilly And Company Benzimidzolyl neuropeptide y receptor antagonists
EP0889034B1 (en) * 1996-03-21 2003-09-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives
AU3295297A (en) * 1996-06-04 1998-01-05 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5)
WO1998003492A1 (en) * 1996-07-23 1998-01-29 Neurogen Corporation Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands
AU3671897A (en) * 1996-07-23 1998-02-10 Neurogen Corporation Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands
EP0915860A1 (en) * 1996-07-23 1999-05-19 Neurogen Corporation Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands
DE69713402T2 (de) * 1996-08-23 2002-11-07 Agouron Pharma Liganden des neuropeptids y
US6043246A (en) * 1996-12-03 2000-03-28 Banyu Pharmaceutical Co., Ltd. Urea derivatives
DE69719544T2 (de) * 1996-12-12 2003-11-06 Banyu Pharmaceutical Co., Ltd. Pyrazolderivate
CA2274593A1 (en) * 1996-12-13 1998-06-18 Banyu Pharmaceutical Co., Ltd. Novel aminopyrazole derivatives
AU7738198A (en) * 1996-12-15 1998-07-15 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
CA2277965A1 (en) * 1997-02-04 1998-08-06 Marc A. Bruce Dihydropyrimidone derivatives as npy antagonists
AU6267198A (en) * 1997-02-14 1998-09-08 Bayer Corporation Amides as npy5 receptor antagonists
JP2002241368A (ja) * 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
WO1998040356A1 (fr) * 1997-03-12 1998-09-17 Banyu Pharmaceutical Co., Ltd. Medicaments contenant des derives d'aminopyridine comme ingredient actif
US5889016A (en) * 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists

Also Published As

Publication number Publication date
KR20010024220A (ko) 2001-03-26
JP2001517651A (ja) 2001-10-09
EP1017672B1 (en) 2002-11-27
SK3602000A3 (en) 2001-01-18
EP1017672A1 (en) 2000-07-12
DE69809782D1 (de) 2003-01-09
BR9812492A (pt) 2000-09-26
DE69809782T2 (de) 2003-07-17
CN1279666A (zh) 2001-01-10
PL339617A1 (en) 2001-01-02
US6127414A (en) 2000-10-03
AU9288998A (en) 1999-04-12
IL134993A0 (en) 2001-05-20
EE200000171A (et) 2001-04-16
NO20001483D0 (no) 2000-03-22
IS5410A (is) 2000-03-20
TR200000785T2 (tr) 2000-09-21
NO20001483L (no) 2000-05-23
SE9703414D0 (sv) 1997-09-23
WO1999015498A1 (en) 1999-04-01
ZA988353B (en) 1999-03-23
CA2303528A1 (en) 1999-04-01
ATE228500T1 (de) 2002-12-15

Similar Documents

Publication Publication Date Title
AR017138A1 (es) Compuestos antagonistas del neuropeptido y, formulaciones farmaceuticas que los incluyen, usos farmaceuticos de tales compuestos y procedimientos parala preparacion de los mismos.
AR033594A1 (es) Un compuesto derivado de 3-aroilindol, su utilizacion, procedimientos para prepararlo, una composicion farmaceutica que lo contiene, un medicamento constituido por dicho compuesto, y compuestos intermediarios
ES2055523T3 (es) Agentes antifungicos de triazol.
DE69124371D1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
TW348178B (en) Octacyclodepsipeptides having an action for killing endoparasites in animals
ATE217629T1 (de) Phosphonooxymethyl oder methylthiomethylether von taxanderivaten als antitumormittel
DK0876366T3 (da) Angiogenese-inhiberende pyridazinaminer
UY24911A1 (es) Compuestos de pirazina útiles en tratamiento de enfermedades y trastornos del snc
ES2132351T3 (es) Compuestos con un grupo sulfamoilo y amidino, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PE20010211A1 (es) Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina
TR200401432T4 (tr) Admantan türevleri
ES2119325T3 (es) Compuestos polienicos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
AR033678A1 (es) Derivados de quinolina, procedimiento para prepararlos, uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados
PA8527401A1 (es) 7-oxo-piridopirimidinas (ii)
DE69933885D1 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
AR044275A1 (es) Uso de derivados de sulfonamidas para la fabricacion de un medicamento para la profilaxis y/o tratamiento de las disfunciones alimentarias
AR037098A1 (es) Proceso para preparar un compuesto intermediario derivado de halo alquil sulfona y compuestos intermediarios que se usan en dicho proceso
DK0888379T3 (da) Forbindelser tilhørende amidinium-familien, farmaceutiske præparater indeholdende disse forbindelser og anvendelsen deraf
AR014146A1 (es) Compuestos de triazina, su uso en terapia, composiciones farmaceuticas que los contienen, proceso para su manufactura e intermediarios de sintesis
AR043271A1 (es) Compuestos de dihidropironas con heterociclos unidos y su uso en composicines farmaceuticas que poseen actividad inhibidora de hiv proteasa
NO964216L (no) Ester- og karbamatderivater av azoloner som er kraftige midler mot Helicobacter
AR032712A1 (es) Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
AR045117A1 (es) Imidazo-pirimidinas y triazolo-pirimidinas:ligandos del receptor de benzodiazepina
DK0658557T3 (da) Eburnan-derivater, fremgangsmåde til fremstilling af sådanne derivater og farmaceutiske sammensætninger indeholdende disse